
IndraLab
Statements
USP14 inhibits Proteasome. 45 / 51
1
|
2
43
reach
"Ubiquitin specific peptidase 14 has been proven to inhibit the proteasome in vitro.21 Ubiquitinated tau is a substrate protein for proteasomal degradation.22 Expressing wild-type USP14 in Usp14 -/- murine embryonic fibroblasts could increase tau expression levels, indicating that USP14 suppressed the ability of the proteasome to degrade tau.23 The deubiquitinating activity of the 19S regulatory particle has recently been proven to be a promising target for cancer treatment."
reach
"As Usp14 negatively regulates proteasome activity by ubiquitin chain disassembly as well as by a noncatalytic mechanism [XREF_BIBR], oleocanthal, in the presence of oxidative stress, has two opposite effects : on one side, it up-regulates the proteasome and, on the other side, it up-regulates Usp14, abrogating the suggested enhancement of the proteasome activity."
reach
"Because K48 linked ubiquitin chains are a robust biomarker of ubiquitin proteasome system function [XREF_BIBR], and we found no difference in the catalytic capacity of TgUsp14CA and wild type proteasomes in vitro, it is unlikely that USP14 inhibition in the nervous system causes global alterations in proteasome activity."
reach
"This decrease in presynaptic transmission with a Usp14 genetic mutant potentially explains the long-term memory deficits in mice treated with a Usp14 inhibitor.Usp14 itself acts as a regulator of proteasome activity, with overexpression of Usp14 inhibiting proteasome function [172]."
reach
"Ubp6 (human USP14) shortens polyubiquitin chains (94) and inhibits proteasome activity (93) possibly to avoid futile degradation of essential proteins during stress.Interestingly, the CP and RP seem to be separately sequestered into PSGs, the CP by Blm10 (28) and the RP by Spg5 (95)."
reach
"Given that several studies have confirmed that USP14 can inhibit the proteasome in vitro [XREF_BIBR, XREF_BIBR, XREF_BIBR] and can inhibit protein turnover in cells [XREF_BIBR] the investigation and development of novel anticancer therapy based on inhibition of proteasome deubiquitinating activity or regulation of protein turnover is indicated."